iVAC-L-CLL01: Patient-individualized Peptide Vaccination in Combination With Lenalidomide After First Line Therapy of CLL

Trial Profile

iVAC-L-CLL01: Patient-individualized Peptide Vaccination in Combination With Lenalidomide After First Line Therapy of CLL

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2016 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
    • 16 Nov 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.
    • 16 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top